Clinical trial
18F-Florbetaben (Neuraceq®) PET/MRI Evaluation of Cardiac Amyloid
NCT03119558 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- 18F-Florbetaben (Neuraceq®) PET/MRI Evaluation of Cardiac Amyloid
- Lead sponsor
- Stanford University
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 26, 2016
- Completion date
- August 28, 2018
- Enrollment
- 9 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cardiac amyloidosis